Eletriptan for the acute treatment of migraine: Results of bridging a Japanese study to Western clinical trials

Current Medical Research and Opinion

Volumn 20, Issue 3, 2004, Pages 269-277

  Sakai, Fumihiko ^a   Diener, H C ^b   Ryan, R ^c   Poole, P ^d  

^a KITASATO UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Ryan Headache Center   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

5 HT1B 1D agonist; Bridging; Headache; Migraine; Pain; Triptan

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; ELETRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SUMATRIPTAN;

ADULT; AGED; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EUROPE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PAIN ASSESSMENT; PARALLEL DESIGN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SYMPTOM; THIRST; THORAX DISEASE; UNITED STATES; VASODILATATION; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALGESICS, NON-NARCOTIC; AUSTRALIA; CLINICAL TRIALS; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; INDOLES; JAPAN; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PYRROLIDINES; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES; UNITED STATES;

EID: 1542406041     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079903125002973     Document Type: Article

References (10)

1. Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000;54(1):156-63
2. Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003;43(3):214-22
3. Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicenter, randomized, double-blind, placebo-controlled comparison. Eletriptan and Cafergot® Comparative Study Group. Eur Neurol 2002;47(2):99-107
4. Stark R, Dahlöf C, Haughie S, Hettiarachchi J. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicenter, placebo-controlled study across three attacks. The Eletriptan Steering Committee. Cephalalgia 2002;22(1):23-32
5. Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. The Eletriptan Steering Committee. Headache 2003;43(3):202-13
6. Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. The Eletriptan Steering Committee. Neurology 2002;59(8):1210-7
7. Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002;22(6):416-23
8. Guideline for Ethnic Factors in the Acceptability of Foreign Clinical Data [online]. Available from http://www.ich.org/ich1bis.html. [Accessed on 20 March 2003]
9. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96
10. Tfelt-Hansen P, Block G, Dahlöf C, Diener HC, Ferrari MD, Goadsby PJ, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20(9):765-86